Asset Details
Do you wish to reserve the book?
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
Do you wish to request the book?
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
2017
Overview
The precise clinicopathologic significance of
myeloid differentiation primary response gene
(
MYD88)
L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the
MYD88
L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified using the PubMed and Embase databases. The effect sizes of outcome parameters were calculated using a random-effects model. In this meta-analysis, the
MYD88
L265P mutation in DLBCL showed a significant difference according to tumor sites. The overall incidence of the
MYD88
L265P mutation in DLBCLs, excluding the central nervous system and testicular DLBCLs, was 16.5%. Notably, the
MYD88
L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively. Interestingly, the
MYD88
L265P mutation was more frequently detected in activated B-cell-like (ABC) or non-germinal center B-cell-like (GCB) than GCB subtype (OR = 3.414, p < 0.001). The
MYD88
L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This pooled analysis demonstrates that the
MYD88
L265P mutation is significantly associated with the tumor sites and molecular subtypes in DLBCL patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
692/4028/67/1990/291/1621/1915
/ Codon
/ Female
/ Humanities and Social Sciences
/ Humans
/ Lymphoma
/ Lymphoma, Large B-Cell, Diffuse - diagnosis
/ Lymphoma, Large B-Cell, Diffuse - genetics
/ Lymphoma, Large B-Cell, Diffuse - mortality
/ Male
/ Mutation
/ Myeloid Differentiation Factor 88 - genetics
/ Science
/ Testes
